Treatment(s) now being considered-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Chemotherapy Posts on Medivizor

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Posted by on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of toripalimab (Tuoyi) in combination with chemotherapy as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that toripalimab in combination with chemotherapy significantly improved overall survival and survival without cancer...

Read More

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Posted by on Dec 31, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of...

Read More

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Posted by on Dec 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...

Read More

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Read More

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Posted by on Feb 25, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of trilaciclib (Cosela) given before gemcitabine (Gemzar) plus capecitabine (Xeloda) (GC) chemotherapy regimen in patients with metastatic triple-negative breast cancer (mTNBC). The data showed that trilaciclib given before GC chemotherapy regimen was effective and significantly improved overall...

Read More

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC.  Some background BC is one of the most common types of cancer found in women. There are...

Read More

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to investigate FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) before pre-surgery chemoradiotherapy (CRT) for patients with rectal cancer (RC). The study found that FOLFIRINOX given before CRT and surgery improved the outcomes of these patients. Some background RC can be treated with...

Read More

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Comparing the effectiveness of different chemotherapy regimens after surgery in early stage breast cancer

Posted by on Apr 21, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of current chemotherapy regimens for treatment in patients with early-stage breast cancer (BC). The data showed that the current treatment regimens have similar effectiveness. Some background BC is classified into different subtypes depending on the presence or...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More

What is the optimal duration of chemotherapy after surgery for patients with stage III colon cancer?

What is the optimal duration of chemotherapy after surgery for patients with stage III colon cancer?

Posted by on Feb 7, 2021 in Colorectal cancer | 0 comments

In a nutshell This trial looked at the length of adjuvant chemotherapy (AC; chemotherapy after surgery) for patients with stage III colon cancer. The authors found that 3 months of AC resulted in similar survival with reduced levels of toxicity, and cost compared to 6 months.  Some background AC has been standard care for patients with...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor